1. [Chronic granulomatous disease: pathogenesis and therapy of associated fungal infections].
- Author
-
Desjardins A, Coignard-Biehler H, Mahlaoui N, Frange P, Bougnoux ME, Blanche S, Fischer A, Blumental S, and Lortholary O
- Subjects
- Animals, Aspergillosis etiology, Aspergillosis immunology, Aspergillosis therapy, Disease Susceptibility, Genetic Therapy, Granulomatous Disease, Chronic enzymology, Granulomatous Disease, Chronic epidemiology, Granulomatous Disease, Chronic immunology, Granulomatous Disease, Chronic surgery, Hematopoietic Stem Cell Transplantation, Humans, Immunocompromised Host, Incidence, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Lymphocyte Subsets immunology, Mice, Mycoses epidemiology, Mycoses immunology, Mycoses prevention & control, Mycoses therapy, NADPH Oxidases deficiency, NADPH Oxidases genetics, NADPH Oxidases physiology, Neutrophils enzymology, Neutrophils immunology, Protein Subunits, Respiratory Burst, Tryptophan metabolism, Anti-Inflammatory Agents therapeutic use, Antifungal Agents therapeutic use, Granulomatous Disease, Chronic complications, Mycoses etiology
- Abstract
Chronic granulomatous disease is a genetic disorder responsible for a defect in the NADPH oxidase of phagocytic cells. It impairs the oxidative burst necessary to the intracellular inactivation of microorganisms and predisposes to an increased risk of infections by various microorganisms, including fungi like Aspergillus spp. and other less frequently encountered or emerging fungal species. Here we review the genetic basis, pathogenesis and clinical presentation associated with fungal infections in chronic granulomatous disease as well as the current prophylaxis and newly available therapies., (© 2012 médecine/sciences โ Inserm / SRMS.)
- Published
- 2012
- Full Text
- View/download PDF